<DOC>
	<DOCNO>NCT00196651</DOCNO>
	<brief_summary>HIV-specific immune response preserve patient treat early primary infection.The trial evaluate whether addition HAART IL-2 alone combine immunization procedure might enhance HIV immune response improve viral control HAART discontinuation</brief_summary>
	<brief_title>HIV Immune Virological Responses Following Administration IL-2 Either Alone Combined ALVAC-HIV 1433 HIV Lipopeptides Patients Treated Early With HAART During Primary Infection</brief_title>
	<detailed_description>HIV-specific immune response preserve patient treat early primary infection . The trial evaluate whether addition HAART IL-2 alone combine immunization procedure might enhance HIV immune response improve viral control HAART discontinuation.Patients treat HAART randomize 3 arm : arm1 HAART alone ; arm2 5 cycle IL-2 wk0 ,8 ,16 ,24 32 ; arm3 4 injection Alvac-HIV 1433 LIPO-6T wk0,4,8 follow 3 cycle IL-2 w 16 , 24 32 . HAART stop wk 40 patient undetectable plasma viral load . Viral load HIV-specific response monitor therapeutic period HAART interruption w52 . HAARTis rei-initiated viral failure .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>History symptomatic HIV primary infection p24 positive incomplete Western Blot Treatment begin 4W first primary infection serology HAART IP NNRTI since one year , wtih change since 3 month Viral load 50 cp since 6 month PN 1000/mm3 ; Hb 10.5g/l ; Platelets 75000/mm3 , creatinine 1.5N ; transaminase 2.5N Vaccination chemotherapy corticosteroid since 3 month Evolutive cancer pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>ALVAC vaccine</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Antiretroviral Therapy , Highly Active</keyword>
</DOC>